Jacobs Levy Equity Management’s Larimar Therapeutics LRMR Stock Holding History

Jacobs Levy Equity Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$520K	Buy	170,575 +1,431	+0.8%	+$5.68K	﹤0.01%	819
2026 Q1	$761K	Buy	+169,144	New	+$676K	﹤0.01%	760
2019 Q4	–	Sell	-22,170	Closed	-$197K	–	1036
2019 Q3	$197K	Buy	22,170 +7,375	+50%	+$80.9K	﹤0.01%	846
2019 Q2	$211K	Buy	14,795 +9,217	+165%	+$246K	﹤0.01%	872
2019 Q1	$183K	Buy	5,578 +1,434	+35%	+$73.5K	﹤0.01%	906
2018 Q4	$246K	Sell	4,144 -3,930	-49%	-$388K	﹤0.01%	842
2018 Q3	$1.13M	Sell	8,074 -217	-3%	-$26.3K	0.02%	629
2018 Q2	$1.02M	Buy	8,291 +4,494	+118%	+$382K	0.02%	661
2018 Q1	$339K	Sell	3,797 -567	-13%	-$48.1K	0.01%	845
2017 Q4	$242K	Sell	4,364 -676	-13%	-$30.5K	﹤0.01%	873
2017 Q3	$213K	Buy	5,040 +508	+11%	+$21.1K	﹤0.01%	849
2017 Q2	$191K	Buy	4,532 +3,100	+216%	+$159K	﹤0.01%	850
2017 Q1	$80K	Sell	1,432 -1,001	-41%	-$49.7K	﹤0.01%	871
2016 Q4	$93K	Buy	+2,433	New	+$98.7K	﹤0.01%	910

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Jacobs Levy Equity Management's LRMR Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Larimar Therapeutics (LRMR) stake by 0.85% in Q2 2026, buying an estimated $5.68K and bringing the position to 170,575 shares worth $520K. The position accounts for ﹤0.01% of the portfolio, ranked #819.

Jacobs Levy Equity Management first reported a position in LRMR in Q4 2016 and has held it in 14 quarters since. The position peaked at $1.13M in Q3 2018. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

Jacobs Levy Equity Management held 170,575 shares of Larimar Therapeutics worth $520K as of Q2 2026.
Jacobs Levy Equity Management bought 1,431 Larimar Therapeutics shares in Q2 2026, an estimated $5.68K.
Larimar Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #819 holding.
Jacobs Levy Equity Management first reported a position in Larimar Therapeutics in Q4 2016 and has held it in 14 quarters since.
Jacobs Levy Equity Management's Larimar Therapeutics position peaked at $1.13M in Q3 2018.
163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.